Objective: To evaluate the influence of the unsaturated to saturated ratio of fatty acids (FAs) reaching the duodenum on postruminal digestion of FAs, mainly focused on stearic acid (C18:0). Materials and Methods: Six Holstein steers [208 ± 3 kg initial live weight (LW)] with cannulas in the abomasum and proximal duodenum were used in a replicated 3 × 3 Latin square design. Steers were fed a fixed amount of a basal steam-flaked corn-based diet containing 8% supple mental fat and were daily infused via abomasum with 0, 67, and 165 gm oleic acid (C18:1). The experiment lasted for 42 days. Results: The daily total FA (TFA) intake (dietary FA intake plus abomasal infusion of oleic acid) represented a 1.78, 2.10, and 2.56 gm TFA/kg LW ratio. The unsaturated to saturated ratio of FAs entering the duodenum increased (p < 0.01) aslevel C18:1 infusion into the abomasum increased. Infusion of C18:1 tended (quadratic component, p = 0.07) to improve postruminal TFA digestion, being maximal for the 67 gm/day infusions. This increase in TFA digestion was due to increased (quadratic component, p = 0.03) postruminal C18:0 digestion (postruminal digestion of the other FAs was not different, p &#8805; 0.13). Conclusion: Increasing the unsaturated to saturated ratio of FAs entering the small intestine will enhance intestinal C18:0 digestion. This positive effect is expected to be more likely bene ficial when FA intake is high (and thus, the duodenal flow of FA is high), but this benefit looks diminished when the quantity of TFA reaching the intestine exceeds the proportion of 2.13 gm FA/kg LW. [J Adv Vet Anim Res 2021; 8(3.000): 465-470]

Abruptly weaned crossbred steer calves (N = 271) were used in a randomized, blinded 2-arm clinical trial to assess the impact of a long-acting non-steroidal anti-inflammatory drug on bovine herpesvirus type 1, bovine respiratory syncytial virus, parainfluenza virus type 3, and coronavirus titers and health outcomes when administered concurrently with a modified live respiratory vaccine upon arrival at a feedlot. Treatment groups included a control (saline; n = 135) and an experimental group (injectable meloxicam; n = 136). Viral antibody titers and body weight were measured on arrival, day 7, and day 21, along with a final weight on day 45. Body weight and antibody titers for all viruses increased over time (P < 0.001); however, there were no differences by treatment group or a significant group × time interaction when evaluated using repeated measures analysis of variance. Interestingly, the use of meloxicam was associated with increased treatment risk (P < 0.05). In conclusion, the administration of meloxicam may adversely affect health; however, a decreased vaccine response is likely not a contributing factor.